Literature DB >> 8242234

Monocrotaline pyrrole-induced changes in angiotensin-converting enzyme activity of cultured pulmonary artery endothelial cells.

C M Hoorn1, R A Roth.   

Abstract

1. Changes in the structural and functional integrity of endothelium have been recognized as relatively early features of delayed and progressive pulmonary vascular injury caused by the pyrrolizidine alkaloid, monocrotaline (MCT). Although a number of investigators have evaluated angiotensin-converting enzyme (ACE) activity in the lungs of rats treated with MCT, the exact nature of changes in activity of this enzyme and the role they may play in MCT pneumotoxicity remain controversial. 2. We examined the direct effects of monocrotaline pyrrole (MCTP), a toxic metabolite of MCT, on cultured endothelial cell ACE activity. Post-confluent monolayers of porcine or bovine pulmonary artery endothelial cells (PECs or BECs, respectively) were treated with a single administration of MCTP at time 0; then they were examined for their ability to degrade the synthetic peptide, [3H]-benzoyl-Phe-Ala-Pro. 3. In PECs, which are relatively insensitive to the direct cytolytic effects of MCTP, monolayer ACE activity was unchanged initially but gradually decreased within 4 days after treatment with a high concentration of MCTP (150 microM). This decrease was transient, and PEC monolayer ACE activity returned to the control value by 10 days post treatment. 4. BEC monolayer ACE activity was also unchanged initially but rapidly declined within 4 days after MCTP treatment and remained depressed throughout the post treatment period. BECs were quite sensitive to the cytolytic effects of MCTP and the decline in ACE activity occurred coincident with the decrease in monolayer cellularity and appearance of marked cytotoxicity. 5. We conclude that high concentrations of MCTP decrease endothelial ACE activity. The decline in ACE activity is delayed and the magnitude and duration of the decrease corresponds to the degree ofMCTP-induced cytotoxicity. This suggests that altered endothelial ACE activity is unlikely to be a direct effect of MCTP on the enzyme but may reflect the delayed cell injury which results from exposure to this compound.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8242234      PMCID: PMC2175927          DOI: 10.1111/j.1476-5381.1993.tb13852.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  42 in total

1.  Prevention of pulmonary vascular changes of chronic alveolar hypoxia by inhibition of angiotensin I-converting enzyme in the rat.

Authors:  R M Zakheim; L Mattioli; A Molteni; K B Mullis; J Bartley
Journal:  Lab Invest       Date:  1975-07       Impact factor: 5.662

2.  Altered removal of vasoactive substances in the injured lung: detection of lung microvascular injury.

Authors:  C N Gillis; J D Catravas
Journal:  Ann N Y Acad Sci       Date:  1982       Impact factor: 5.691

3.  The effect of a pyrrolizidine alkaloid, monocrotaline, and a pyrrole, dehydroretronecine, on the biochemical functions of the pulmonary endothelium.

Authors:  R Huxtable; D Ciaramitaro; D Eisenstein
Journal:  Mol Pharmacol       Date:  1978-11       Impact factor: 4.436

4.  Alterations in pulmonary alveoli after a single injection of monocrotaline.

Authors:  E Valdivia; J J Lalich; Y Hayashi; J Sonnad
Journal:  Arch Pathol       Date:  1967-07

5.  The effects of monocrotaline pyrrole on cultured bovine pulmonary artery endothelial and smooth muscle cells.

Authors:  J F Reindel; R A Roth
Journal:  Am J Pathol       Date:  1991-03       Impact factor: 4.307

6.  Early effects of ionizing radiation on pulmonary endothelial angiotensin-converting enzyme and 5'-nucleotidase, in vivo.

Authors:  J D Catravas; S E Burch; B O Spurlock; L R Mills
Journal:  Toxicol Appl Pharmacol       Date:  1988-07       Impact factor: 4.219

7.  Influence of the angiotensin system on endothelial and smooth muscle cell migration.

Authors:  L Bell; J A Madri
Journal:  Am J Pathol       Date:  1990-07       Impact factor: 4.307

8.  The proliferative response to vascular injury is suppressed by angiotensin-converting enzyme inhibition.

Authors:  J S Powell; R K Müller; M Rouge; H Kuhn; F Hefti; H R Baumgartner
Journal:  J Cardiovasc Pharmacol       Date:  1990       Impact factor: 3.105

9.  Comparison of response of bovine and porcine pulmonary arterial endothelial cells to monocrotaline pyrrole.

Authors:  J F Reindel; C M Hoorn; J G Wagner; R A Roth
Journal:  Am J Physiol       Date:  1991-12

10.  Expression of angiotensin-converting enzyme activity in cultured pulmonary artery endothelial cells.

Authors:  P J Del Vecchio; J R Smith
Journal:  J Cell Physiol       Date:  1981-09       Impact factor: 6.384

View more
  1 in total

1.  Liraglutide prevents and reverses monocrotaline-induced pulmonary arterial hypertension by suppressing ET-1 and enhancing eNOS/sGC/PKG pathways.

Authors:  Mei-Yueh Lee; Kun-Bow Tsai; Jong-Hau Hsu; Shyi-Jang Shin; Jiunn-Ren Wu; Jwu-Lai Yeh
Journal:  Sci Rep       Date:  2016-09-01       Impact factor: 4.379

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.